The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

Germany's Merck KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer.

Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...

Merck's pipeline includes a number of drug candidates in clinical trials for haematological malignancies, including BTK inhibitor nemtabrutinib (MK-1026), anti-LAG-3 antibody favelizumab (MK-4280 ...

Oral inhalation is an attractive route of administration because the drug is delivered directly to the site of action, where it can have a local and immediate effect. Asthma is one of the most ...

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators ... In vaccines, Merck’s pneumococcal disease vaccine Capvaxive was recommended ...

indicates confidence in the drug’s efficacy but still requires further data presentation for comprehensive evaluation. While the trial’s early success and Merck’s increased sales guidance ...

Jan 24 (Reuters) - Merck (MRK.N), opens new tab and Japan-based Eisai (4523.T), opens new tab said on Friday a combination of their therapies failed to extend the lives of patients with a type of ...